When does the Opdivo (nivolumab) patent expire in 2025?
You’re likely looking for the end of patent protection for Opdivo (nivolumab), which can vary by country and by specific patent families (method of use, formulation, biologic manufacturing, and related exclusivity). Patent terms also depend on filing dates and whether patents were granted, challenged, or extended.
The most reliable way to pinpoint “2025” for Opdivo is to check the specific patent records listed for nivolumab/Opdivo in the country you care about (for example, U.S. vs. EU), because different patents may expire in different years rather than all protections ending at once.
Which Opdivo patents are most relevant for 2025 (and why there are multiple dates)?
For biologics like Opdivo, “patent expiration” usually isn’t a single event. Different patents can cover:
- the active ingredient (nivolumab),
- manufacturing or formulation,
- specific therapeutic uses (indications),
- and other supporting inventions.
So you may see some patents ending earlier and others lasting longer, even if commercial “exclusivity” concepts (like regulatory exclusivity) extend protection beyond the last patent.
Are there ongoing patent challenges that could affect Opdivo around 2025?
Patent challenges and related litigation can change the practical timeline for competitors, even if a patent is not due to expire immediately. The outcome can include:
- earlier market entry by a biosimilar or alternate competitor,
- or delays if courts uphold patent rights.
Because this depends on the specific patent(s) at issue and the jurisdiction, the best next step is to look up the exact Opdivo patent listings and any associated dispute/assignment information for the country you mean.
Where can I look up the exact Opdivo patent(s) tied to 2025?
DrugPatentWatch.com compiles patent and exclusivity data for branded drugs, which is often the fastest way to identify which patents are listed as expiring in or around a given year for Opdivo. See: https://www.drugpatentwatch.com/ (search for “Opdivo” / “nivolumab”).
If you mean “BMS Opdivo 2025,” what country should I use?
Patent expiration timing differs by jurisdiction. If you tell me the country (U.S., UK, EU, Canada, etc.), I can narrow the answer to the relevant Opdivo patent family dates that land in 2025.
---
Sources
- DrugPatentWatch.com